finance.yahoo.com/news/...cquires-issued-patent-123000377.htmlRegen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell
Regen Has Raised Almost $700,000 From "Angel" Investors Since December 29, 2014 to Finance Its Ongoing Research
SAN DIEGO, CA, Mar 10, 2015 (Marketwired via COMTEX) -- Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today successful closing of a transaction resulting in acquisition of issued US patent
#8,263,571, and associated preclinical data package. The intellectual property covers specific therapeutic agents that gene silence CTCFL. CTCFL, otherwise known as Brother of the Regulator of Imprinted Sites (BORIS) is a gene that is critical for cancer stem cells to survive, in part by inducing expression of telomerase, a protein that creates cellular immortality(1)...............